{
    "clinical_study": {
        "@rank": "68638", 
        "arm_group": {
            "arm_group_label": "Lamazym", 
            "arm_group_type": "Experimental", 
            "description": "1 mg/kg body weight"
        }, 
        "brief_summary": {
            "textblock": "The overall objective is to evaluate the long-term efficacy, safety and tolerability of\n      repeated Lamazym i.v. treatment in patients 5-21 years of age with alpha-Mannosidosis"
        }, 
        "brief_title": "Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Alpha-Mannosidosis", 
        "condition_browse": {
            "mesh_term": [
                "Alpha-Mannosidosis", 
                "Mannosidase Deficiency Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject must have participated in the phase 1 trial (EudraCT number:\n             2010-022084-36) and phase 2a trial (EudraCT number: 2010-022085-26)\n\n          -  Subject or subjects legally authorized guardian(s) must provide signed, informed\n             consent prior to performing any trial-related activities (trial-related activities\n             are any procedures that would not have been performed during normal management of the\n             subject)\n\n          -  The subject and his/her guardian(s) must have the ability to comply with the protocol\n\n        Exclusion Criteria:\n\n          -  The subject cannot walk without support\n\n          -  Presence of known chromosomal abnormality and syndromes affecting psychomotor\n             development, other than alpha-Mannosidosis\n\n          -  History of bone marrow transplantation\n\n          -  Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal\n             disease or other medical conditions that, in the opinion of the Investigator, would\n             preclude participation in the trial\n\n          -  Any other medical condition or serious intercurrent illness, or extenuating\n             circumstance that, in the opinion of the investigator, would preclude participation\n             in the trial.\n\n          -  Pregnancy: Before the start of the treatment the investigators will decide whether or\n             not there is a need for contraception. This assessment will be done through\n             interviews with the patient and parents. The evaluation will be done continuously\n             during the study\n\n          -  Psychosis within the last 3 months\n\n          -  Planned major surgery that, in the opinion of the investigator, would preclude\n             participation in the trial\n\n          -  Participation in other interventional trials testing IMP except for studies with\n             Lamazym"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681940", 
            "org_study_id": "rhLAMAN-04", 
            "secondary_id": "2011-004355-40"
        }, 
        "intervention": {
            "arm_group_label": "Lamazym", 
            "description": "ERT, i.v. infusions weekly", 
            "intervention_name": "Lamazym", 
            "intervention_type": "Drug", 
            "other_name": [
                "rhLAMAN", 
                "recombinant human alpha-mannosidase"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 5, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brussel", 
                        "country": "Belgium", 
                        "zip": "1090"
                    }, 
                    "name": "Kinderneurologie Metabole Ziekten, UZ Brussel, Laarbeeklaan 101"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "DK-2100"
                    }, 
                    "name": "Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "C\u00f3rdoba", 
                        "country": "Spain", 
                        "zip": "14004"
                    }, 
                    "name": "Servicio de Pediatr\u00eda, Hospital Materno Infantil, Reina Sof\u00eda, Avda Men\u00e9ndez Pidal sn"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M13 9WL"
                    }, 
                    "name": "Genetic Medicine, 6th floor, St Mary's Hospital, Oxford Road,"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Denmark", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-Center, Open-Label Trial of the Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis", 
        "overall_official": [
            {
                "affiliation": "Copenhagen University Hospital, Center for Metabolic Diseases, Department for Clinical Genetics", 
                "last_name": "Allan M Lund, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Zymenex A/S", 
                "last_name": "Jens Fogh", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Medicines Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Belgium: Federal Agency for Medicinal Products and Health Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Efficacy endpoint evaluation as change from baseline", 
            "measure": "Reduction of Oligosaccharides in blood serum", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681940"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Efficacy endpoint evaluation as change from baseline", 
                "measure": "The number of steps climbed in 3 minutes (3-minute stair climb)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Efficacy endpoint evaluation as change from baseline", 
                "measure": "Reduction of Oligosaccharides in CSF", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Efficacy endpoint evaluation as change from baseline", 
                "measure": "The distance walked in 6 minutes (6-minute walk test)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Efficacy endpoint evaluation as change from baseline", 
                "measure": "Pulmonary function", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Safety endpoint assesed weekly throughout the trial", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Safety endpoint assesed weekly throughout the trial", 
                "measure": "Development of clinically significant changes in vital signs and change in physical examination", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Safety endpoint assesed weekly throughout the trial", 
                "measure": "Development of clinically significant changes in the clinical laboratory parameters (hematology, biochemistry and urinalysis)", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Safety endpoint assesed weekly throughout the trial", 
                "measure": "Development of rhLAMAN antibodies and neutralizing/inhibitory antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }
        ], 
        "source": "Zymenex A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "European Commission", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Zymenex A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}